Please login to the form below
opicapone
This page shows the latest opicapone news and features for those working in and with pharma, biotech and healthcare.
Neurocrine bags FDA approval for first tardive dyskinesia drug
The company fleshed out its movement disorder pipeline earlier this year by licensing opicapone from Portuguese drug maker BIAL.
Latest news
-
EC approves Bial’s Parkinson’s disease therapy
Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Opicapone is a third-generation
-
Chasing the cure for Parkinson's disease
Opicapone (Bial) is a COMT inhibitor in phase III development in various European countries for the treatment of idiopathic Parkinson's. ... Bial plans to develop opicapone to be administered in combination with levodopa/carbidopa or
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Medical Writers
-
Competitive Salary and Benefits
-
Senior Medical Writer
-
Competitive Salary
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director
-
Excellent benefits
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Associate Director
-
£75, 000-90, 000
-
Associate Medical Director
-
Highly Competitive
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Account Director
-
£48, 000 - £60, 000
- Director, Market Access / HEOR - North-West
-
Negotiable
-
New Business Director - PR
-
Competitive Salary and benefits
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
- Oral Appliances lead Sleep Apnea Devices Market Growth, Shows Recent Analysis
- Animal Healthcare Market is poised to cross USD 36 billion by 2024
- Fishawack launches new website and introduces new structure for growth
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- Orphan drugs from Biogen and Amicus win UK Prix Galien
- AZ’s MYSTIC survival data is in – and it’s a bust
PMHub
Ashfield
Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
